Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Corrigendum to: Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.

Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H, Goto Y, Yoshida K, Ohde Y, Okumura S, Ohashi Y, Kunitoh H.

Jpn J Clin Oncol. 2020 Feb 17. pii: hyaa012. doi: 10.1093/jjco/hyaa012. [Epub ahead of print] No abstract available.

PMID:
32065232
2.

Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.

Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, Murase K, Tsukita Y, Ashinuma H, Nakagawa T, Uematsu K, Nakao M, Mori Y, Kaira K, Mouri A, Miyabayashi T, Sakashita H, Matsumoto Y, Tanigawa T, Koizumi T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2019 Nov 26. pii: theoncologist.2019-0593. doi: 10.1634/theoncologist.2019-0593. [Epub ahead of print]

3.

Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.

Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K.

Thorac Cancer. 2020 Jan;11(1):140-149. doi: 10.1111/1759-7714.13255. Epub 2019 Nov 22.

4.

The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.

Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP.

J Thorac Oncol. 2019 Jun;14(6):1061-1076. doi: 10.1016/j.jtho.2019.02.019. Epub 2019 Feb 27.

PMID:
30825612
5.

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.

Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y.

Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.

PMID:
30642448
6.

Germline mutations in lung cancer.

Shukuya T, Takahashi K.

Respir Investig. 2019 May;57(3):201-206. doi: 10.1016/j.resinv.2018.12.005. Epub 2019 Jan 11. Review.

PMID:
30639082
7.

Pattern of care in adjuvant therapy for resected Stage I non-small cell lung cancer: real-world data from Japan.

Yoh K, Takamochi K, Shukuya T, Hishida T, Tsuboi M, Sakurai H, Goto Y, Yoshida K, Ohde Y, Okumura S, Ohashi Y, Kunitoh H.

Jpn J Clin Oncol. 2019 Jan 1;49(1):63-68. doi: 10.1093/jjco/hyy165.

PMID:
30452719
8.

Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study.

Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group.

Oncologist. 2018 Oct;23(10):1210-1217. doi: 10.1634/theoncologist.2017-0586. Epub 2018 Mar 22.

9.

Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations.

Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP.

Mol Cancer Ther. 2018 Jan;17(1):17-25. doi: 10.1158/1535-7163.MCT-17-0146. Epub 2017 Oct 27.

10.

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.

Shukuya T, Patel S, Shane-Carson K, He K, Bertino EM, Shilo K, Otterson GA, Carbone DP.

J Thorac Oncol. 2018 Feb;13(2):e17-e19. doi: 10.1016/j.jtho.2017.09.1962. Epub 2017 Oct 5. No abstract available.

11.

Significant changes of T2 value in the peripheral zone and seminal vesicles after ejaculation.

Shin T, Kaji Y, Shukuya T, Nozaki M, Soh S, Okada H.

Eur Radiol. 2018 Mar;28(3):1009-1015. doi: 10.1007/s00330-017-5077-4. Epub 2017 Oct 6.

PMID:
28986624
12.

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.

Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.

PMID:
28501140
13.

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.

Nakamura K, Kato M, Shukuya T, Mori K, Sekimoto Y, Ihara H, Kanemaru R, Ko R, Shibayama R, Tajima K, Koyama R, Shimada N, Nagashima O, Takahashi F, Sasaki S, Takahashi K.

BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.

14.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP.

J Thorac Oncol. 2016 Nov;11(11):1927-1939. doi: 10.1016/j.jtho.2016.07.017. Epub 2016 Aug 3.

15.

A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.

Yamada K, Ichiki M, Takahashi K, Hisamatsu Y, Takeoka H, Azuma K, Shukuya T, Nishikawa K, Tokito T, Ishii H, Hoshino T.

Cancer Chemother Pharmacol. 2016 Sep;78(3):501-7. doi: 10.1007/s00280-016-3101-z. Epub 2016 Jul 11.

PMID:
27402398
16.

Bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in non-small cell lung cancer.

Sekimoto Y, Kato M, Shukuya T, Koyama R, Nagaoka T, Takahashi K.

Respirol Case Rep. 2016 Mar 31;4(2):e00151. doi: 10.1002/rcr2.151. eCollection 2016 Apr. Erratum in: Respirol Case Rep. 2016 Jul;4(4):e00166.

17.

Cerebral infarction in advanced non-small cell lung cancer: a case control study.

Kato M, Shukuya T, Mori K, Kanemaru R, Honma Y, Nanjo Y, Muraki K, Shibayama R, Koyama R, Shimada N, Takahashi F, Takahashi K.

BMC Cancer. 2016 Mar 10;16:203. doi: 10.1186/s12885-016-2233-1.

18.

Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer.

Shukuya T, Carbone DP.

J Thorac Oncol. 2016 Jul;11(7):976-88. doi: 10.1016/j.jtho.2016.02.015. Epub 2016 Mar 2. Review.

19.

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.

Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S, Takahashi K.

Respir Investig. 2016 Jan;54(1):14-9. doi: 10.1016/j.resinv.2015.07.001. Epub 2015 Aug 30.

PMID:
26718140
20.

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group.

Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28.

PMID:
26522337
21.

Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents.

Shukuya T, Ko R, Mori K, Kato M, Yagishita S, Kanemaru R, Honma Y, Shibayama R, Koyama R, Shimada N, Takahashi K.

Cancer Chemother Pharmacol. 2015 Oct;76(4):771-6. doi: 10.1007/s00280-015-2843-3. Epub 2015 Aug 11.

PMID:
26259641
22.

The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients.

Miura S, Kaira K, Kaira R, Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Invest New Drugs. 2015 Jun;33(3):755-60. doi: 10.1007/s10637-015-0233-7. Epub 2015 Apr 7.

PMID:
25846908
23.

Disease flare after gefitinib discontinuation.

Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T.

Respir Investig. 2015 Mar;53(2):68-72. doi: 10.1016/j.resinv.2014.10.005. Epub 2014 Nov 13.

PMID:
25745851
24.

Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).

Hishida T, Tsuboi M, Shukuya T, Takamochi K, Sakurai H, Yoh K, Ohashi Y, Kunitoh H.

Jpn J Clin Oncol. 2015 May;45(5):499-501. doi: 10.1093/jjco/hyv028. Epub 2015 Feb 26.

PMID:
25724215
25.

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.

Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T.

Ann Thorac Med. 2015 Jan-Mar;10(1):61-6. doi: 10.4103/1817-1737.146885.

26.

The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.

Ko R, Kenmotsu H, Hisamatsu Y, Akamatsu H, Omori S, Nakashima K, Oyakawa T, Wakuda K, Shukuya T, Ono A, Imai H, Taira T, Naito T, Murakami H, Mori K, Endo M, Ohde Y, Takahashi K, Takahashi T.

Int J Clin Oncol. 2015 Aug;20(4):668-73. doi: 10.1007/s10147-014-0761-8. Epub 2014 Oct 25.

PMID:
25343946
27.

Identification of actionable mutations in malignant pleural mesothelioma.

Shukuya T, Serizawa M, Watanabe M, Akamatsu H, Abe M, Imai H, Tokito T, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Ohde Y, Nakajima T, Yamamoto N, Koh Y.

Lung Cancer. 2014 Oct;86(1):35-40. doi: 10.1016/j.lungcan.2014.08.004. Epub 2014 Aug 18.

PMID:
25174276
28.

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease.

Kato M, Shukuya T, Takahashi F, Mori K, Suina K, Asao T, Kanemaru R, Honma Y, Muraki K, Sugano K, Shibayama R, Koyama R, Shimada N, Takahashi K.

BMC Cancer. 2014 Jul 10;14:508. doi: 10.1186/1471-2407-14-508.

29.

Multiplexed molecular profiling of lung cancer using pleural effusion.

Akamatsu H, Koh Y, Kenmotsu H, Naito T, Serizawa M, Kimura M, Mori K, Imai H, Ono A, Shukuya T, Taira T, Murakami H, Ohde Y, Endo M, Nakajima T, Takahashi T, Yamamoto N.

J Thorac Oncol. 2014 Jul;9(7):1048-52. doi: 10.1097/JTO.0000000000000203.

30.

Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions.

Tokito T, Shukuya T, Akamatsu H, Ono A, Taira T, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Mori K, Yamamoto N.

Respir Investig. 2014 May;52(3):184-9. doi: 10.1016/j.resinv.2013.12.004. Epub 2014 Jan 17.

PMID:
24853019
31.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.

Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.

Respir Investig. 2014 Mar;52(2):101-6. doi: 10.1016/j.resinv.2013.07.002. Epub 2013 Sep 13.

PMID:
24636265
32.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Review.

PMID:
24636263
33.

Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.

Hisamatsu Y, Murakami H, Akamatsu H, Kimura M, Mori K, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Naito T, Endo M, Nakajima T, Takahashi T, Yamamoto N.

Thorac Cancer. 2014 Mar;5(2):121-5. doi: 10.1111/1759-7714.12071. Epub 2014 Mar 3.

34.

Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.

Imai H, Shukuya T, Yoshino R, Muraki K, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Tomizawa Y, Takahashi T, Takahashi K, Saito R, Yamamoto N.

Chemotherapy. 2013;59(4):307-13. doi: 10.1159/000356155. Epub 2014 Jan 24.

PMID:
24480845
35.

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Akamatsu H, Mori K, Naito T, Imai H, Ono A, Shukuya T, Taira T, Kenmotsu H, Murakami H, Endo M, Harada H, Takahashi T, Yamamoto N.

BMC Cancer. 2014 Jan 14;14:18. doi: 10.1186/1471-2407-14-18.

36.

Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.

Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Yamamoto N.

Neoplasma. 2014;61(2):233-40. doi: 10.4149/neo_2014_030.

PMID:
24299320
37.

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Imai H, Shukuya T, Takahashi T, Fujiwara S, Mori K, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Harada H, Endo M, Nakajima T, Yamamoto N.

Anticancer Res. 2013 Aug;33(8):3279-84.

PMID:
23898092
38.

Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.

Ono A, Takahashi T, Mori K, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Nakajima T, Endo M, Yamamoto N.

BMC Cancer. 2013 Jul 23;13:354. doi: 10.1186/1471-2407-13-354.

39.

Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib.

Ono A, Takahashi T, Oishi T, Sugino T, Akamatsu H, Shukuya T, Taira T, Kenmotsu H, Naito T, Murakami H, Nakajima T, Endo M, Yamamoto N.

J Clin Oncol. 2013 Sep 10;31(26):e417-9. doi: 10.1200/JCO.2012.47.1110. Epub 2013 Jul 15. No abstract available.

PMID:
23857970
40.

Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.

Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Shukuya T, Ono A, Akamatsu H, Watanabe R, Ono S, Mori K, Kanbara H, Yamaguchi K, Tanaka T, Matsunaga T, Yamamoto N.

PLoS One. 2013 Jun 28;8(6):e67466. doi: 10.1371/journal.pone.0067466. Print 2013.

41.

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A.

BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262.

42.

Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.

Tokito T, Shukuya T, Akamatsu H, Taira T, Ono A, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1493-8. doi: 10.1007/s00280-013-2148-3. Epub 2013 Mar 27.

PMID:
23532208
43.

Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.

Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N.

Am J Clin Oncol. 2015 Feb;38(1):28-32. doi: 10.1097/COC.0b013e318286907b.

PMID:
23388567
44.

Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens.

Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, Nakamura Y, Tsuya A, Naito T, Murakami H, Takahashi T, Ohde Y, Kondo H, Endo M, Kameya T, Nakajima T, Mori K, Yamamoto N.

Int J Clin Oncol. 2014 Feb;19(1):63-7. doi: 10.1007/s10147-012-0509-2. Epub 2012 Dec 19.

PMID:
23250620
45.

Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older.

Shukuya T, Takahashi T, Harada H, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N.

Jpn J Clin Oncol. 2013 Feb;43(2):176-83. doi: 10.1093/jjco/hys197. Epub 2012 Dec 5.

PMID:
23225910
46.

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.

Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N.

Am J Clin Oncol. 2014 Apr;37(2):144-7. doi: 10.1097/COC.0b013e31826e04f9.

PMID:
23211219
47.

Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.

Muraki K, Koyama R, Honma Y, Yagishita S, Shukuya T, Ohashi R, Takahashi F, Kido K, Iwakami S, Sasaki S, Iwase A, Takahashi K.

J Thorac Dis. 2012 Dec;4(6):562-8. doi: 10.3978/j.issn.2072-1439.2012.10.16.

48.

Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.

Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N.

Respir Investig. 2012 Dec;50(4):157-61. doi: 10.1016/j.resinv.2012.09.002. Epub 2012 Oct 27.

PMID:
23199980
49.

[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].

Murakami A, Ohashi R, Minakata K, Koyama R, Muraki K, Shukuya T, Namba Y, Ko R, Yagishita S, Katsura Y, Takahashi F, Sakuraba S, Takahashi K.

Gan To Kagaku Ryoho. 2012 Sep;39(9):1357-61. Japanese.

PMID:
22996769
50.

A comparative study between arterial spin labeling and CT perfusion methods on hepatic portal venous flow.

Katada Y, Shukuya T, Kawashima M, Nozaki M, Imai H, Natori T, Tamano M.

Jpn J Radiol. 2012 Dec;30(10):863-9. doi: 10.1007/s11604-012-0127-y. Epub 2012 Sep 19.

PMID:
22986750

Supplemental Content

Loading ...
Support Center